ECOR electroCore

electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

Conference Call to be Held at 4:30pm Eastern Time

BASKING RIDGE, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market on Thursday, May 14, 2020.  Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

 
Thursday, May 14 @ 4:30pm Eastern Time

Domestic: 877-407-4018
International: 201-689-8471 
Conference ID: 13702250
Webcast:
  

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit .

Investors:

Hans Vitzthum

LifeSci Advisors

617-430-7578

or

Media Contact:

Jackie Dorsky

electroCore

973-290-0097

EN
07/05/2020

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were...

23h / 14m 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctiv...

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 mil...

September 30, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/I...

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clin...

September 29, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Andy Brown has joined electroCore, effective September 9, 2025, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Brown in connection with the commencement of his employment. The RSUs were granted as an inducement material...

September 10, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Departure of Peter Cuneo from the Board of Direc...

electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. “I want to offer my gratitude, and my congratulations...

September 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch